Early Loss of Fat Mass During Chemoradiotherapy Predicts Overall Survival in Locally Advanced Squamous Cell Carcinoma of the Lung, but Not in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

A. C. H. Willemsen, J. H. R. J. Degens, L. W. J. Bajens, A-M. C. Dingemans, A. Hoeben, F. J. P. Hoebers, D. K. M. De Ruyscher, and A. M. W. J. Schols

Background: Cancer cachexia is highly prevalent in advanced non-small cell lung cancer (NSCLC) and locally advanced head and neck squamous cell carcinoma (LAHNSCC), and compromises treatment tolerance and overall survival (OS). NSCLC and LAHNSCC patients share similar risk factors, and receive comparable anti-cancer treatment regimens. The aim of this study was to determine the predictive value of body composition assessed by bioelectrical impedance analysis (BIA) and handgrip strength (HGS) (baseline and early changes during therapy) on OS in NSCLC and LAHNSCC patients treated with platinum-based chemoradiotherapy (CRT) or cetuximab-based bioradiotherapy (BRT). To elucidate potential underlying determinants of early changes in body composition and HGS, specific (fat and fat free) mass loss patterns of squamous NSCLC (sNSCLC) were compared to human papilloma virus negative (HPV–) LAHNSCC patients treated with CRT.

Methods: Between 2013 and 2016, BIA and HGS were performed at baseline and after 3 weeks of CRT/BRT in LAHNSCC and NSCLC patients treated with curative intent.

Results: Two hundred thirty-three patients were included for baseline measurements. Fat free mass index (FFMI) and HGS < 10th percentile of reference values at baseline were both prognostic for poor OS in NSCLC and LAHNSCC [HR 1.64 [95%CI 1.13–2.39], p = 0.01 and HR 2.30 [95%CI 1.33–3.97], p = 0.003, respectively], independent of Charlson Comorbidity Index, cancer site, and gross tumor volume. Early fat mass
INTRODUCTION

In clinical practice, patients with head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) share comparable disease and patient characteristics. For example, smoking is a risk factor for developing both cancer types and histopathologically, in case of squamous cell carcinoma (SCC), one cannot easily distinguish HNSCC from NSCLC (1, 2). Furthermore, the prevalence of comorbidity such as chronic obstructive pulmonary disease (COPD) and cardiovascular disease is high in both HNSCC and NSCLC (3–6).

Before the introduction of immunotherapy, standard treatment of locally advanced NSCLC (stage III) included platinum-based chemoradiotherapy (CRT) with disappointing 3 and 5-year overall survival (OS) rates of 43 and 30% (7). However, addition of treatment with durvalumab after concurrent CRT has improved OS to a 3-year OS rate of 57% (8). CRT regimens are also being used in patients with locally advanced HNSCC (LAHNSCC, stage III–IV), and their 5-year OS rates of 34–49% are slightly higher (9, 10). To improve success rates of CRT, it is highly desirable that patients’ physical condition and body composition is optimal upon start and maintained during treatment, so patients are more likely to complete the planned treatment trajectory without interruptions of chemotherapy and/or radiation dose reduction due to grade 3–4 toxicity (11–15).

The efficacy of treatment is not only dependent on tumor aspects, but research in many cancer populations has shown that individual patient characteristics including body weight and body composition play an important role. Cancer cachexia, a multifactorial syndrome characterized by an ongoing loss of skeletal muscle mass, (16) is known for being a negative prognostic factor in a wide range of cancer patients, including locally advanced NSCLC and LAHNSCC (17). A significant adverse effect of early weight loss during CRT on OS was observed in stage III NSCLC patients, independent of the onset of therapy induced esophagitis (18–21). In LAHNSCC, significant weight loss was also observed in the first 3 weeks of CRT, which is before onset of the expected therapy induced oral and pharyngeal mucositis (22, 23). In addition to body weight, data on body composition and the presence of sarcopenia/cancer cachexia, could provide information on the expected prognosis of the patient and may therefore support the multidisciplinary team in clinical decision-making. Loss of skeletal muscle mass on CT scans is a strong predictor for poor prognosis in both NSCLC and head and neck cancer (24–26). However, this technique is expensive and time consuming and therefore not routinely feasible in daily clinical practice. Bioelectrical impedance analysis (BIA) combined with handgrip strength (HGS) measurements can easily be implemented in daily clinical care and in a community setting to assess fat mass (FM), fat free mass (FFM), and muscle strength, during treatment (27). Studies have shown that loss of FM and FFM during therapy measured by BIA were correlated to loss of health-related quality of life (28, 29). However, the effect of specific (fat or fat free) body mass loss during the first 3 weeks of treatment on OS, measured by BIA and HGS, has not been investigated for locally advanced NSCLC and LAHNSCC. The aim of this study was to assess the relationship between FM, FFM, and HGS at baseline and changes hereof during first 3 weeks of treatment on the one hand vs. OS on the other hand in advanced cancer patients treated with concurrent CRT or cetuximab-based bioradiation (BRT) with curative intent. In order to clarify potential underlying determinants of changes in body composition and HGS, we also compared specific (fat and fat free) mass loss patterns of NSCLC to LAHNSCC patients.

Keywords: hand grip strength (HGS), locally advanced (stage III) non-small cell lung cancer, locally advanced head and neck cancer, bioelectrical impedance analysis, cachexia, weight loss, chemoradiotherapy (CRT)
Because differences in histology (squamous vs. non-squamous), tumorigenesis (human papilloma virus positive (HPV+) vs. HPV negative (HPV–), and treatment ( cetuximab vs. platinum based) may influence metabolism and therapy response (30–33), this analysis is performed in a more homogeneous subgroup of squamous NSCLC (sNSCLC) and HPV– LAHNSCC patients treated with platinum-based CRT. We hypothesize that a low fat free mass index (FFMI), as a proxy for total body muscle mass, before start of treatment is a negative predictor for OS in both locally advanced NSCLC and LAHNSCC. We expect total weight loss and in particular FM loss to be higher in LAHNSCC due to an additional impaired oral intake in a subset of these patients, depending on tumor site, the presence of oropharyngeal dysphagia, prior head and neck surgery, and dental extraction prior to receiving high dose radiotherapy (34, 35). Presuming comparable treatment induced systemic catabolic activity in LAHNSCC and NSCLC patients, we expect no differences between the groups in FFM changes during the first 3 weeks of CRT.

MATERIALS AND METHODS

Study Design and Population

Patients were followed as part of a larger prospective cohort study conducted at MAASTRO Clinic, Maastricht University Medical Center (MUMC+), Maastricht, the Netherlands (ClinicalTrials.gov Identifier: NCT01985984, LAHNSCC population only). The Institutional Review Board of MAASTRO Clinic approved the study. Patients with stage III NSCLC were referred from four different hospitals in the Netherlands to MAASTRO Clinic for radiotherapy as part of a concurrent platinum-based CRT protocol with curative intent between January 2013 and June 2015. Patients with LAHNSCC undergoing primary or adjuvant concurrent CRT/BRT with curative intent in MAASTRO Clinic and MUMC+ between 2013 and 2016 were included. All patients with body weight assessment, BIA measurements, and HGS measurements at baseline and during week 3 of treatment were included in the study. Patients presenting concurrent malignancies beside the locally advanced NSCLC or LAHNSCC were excluded.

First, the effect of baseline characteristics on OS (part I) was evaluated in NSCLC and LAHNSCC patients undergoing radiotherapy and any concurrent systemic therapy.

In order to elucidate possible underlying mechanisms contributing to weight loss in the first 3 weeks of therapy in both patient groups (part II), exclusion of potential confounders was considered essential. Only patients with SCC were included in the second part of this study. LAHNSCC patients receiving cetuximab as radiosensitizer, and tumors that were positive for P16 (P16+), a surrogate marker for HPV, were excluded. In this cohort, the P16 status was available for all oropharyngeal tumors, but subsequent HPV RT-PCR analysis was not performed in all cases. For the convenience of the reader, P16+ tumors are referred to as HPV+ in this manuscript.

Oncological Treatment

For NSCLC, the concurrent systemic therapy consisted of three cycles of cisplatin (100 mg/m² q3w) or carboplatin (AUC5 on day 1) in combination with etoposide (100 mg/m² day 1–3) administered every 3 weeks. Radiotherapy was applied in 30–33 daily fractions of 2 Gy up to a total dose of 60–66 Gy (36, 37).

In LAHNSCC patients, concurrent cisplatin was administered intravenously on days 1, 22, and 43, in doses of 100 mg/m² in case of primary and adjuvant treatment (15, 38). Adjuvant CRT was given in case of extra nodal extension in neck dissections and/or irradical tumor resection margins. In case of contraindications for cisplatin, and only in a primary treatment setting, cetuximab was administered weekly in doses of 250 mg/m², preceded by a loading dose of 400 mg/m², 1 week before radiotherapy initiation in a primary treatment setting only (14). Radiotherapy was applied in 33–35 fractions up to a total dose of 66–70 Gy.

Measurements

Body composition was assessed using single-frequency (50 kHz) BIA (Omron Healthcare Group, Hoofddorp, The Netherlands). FFMI was calculated by dividing FFm in kg by height in meters squared. Low FFMI was defined as a FFMI below the 10th percentile (FFMI<P10), corrected for age and gender according to Schutz et al. (39).

HGS was measured with a Jamar hydraulic hand dynamometer (JA Preston Corporation, Jackson, MI, USA). The measurements were repeated three times for the left and right hand and the highest value for both sides was registered. Follow up HGS was chosen based on the side with the highest value at baseline. Low HGS was defined as HGS below the 10th percentile (HGS<P10) of the UK Biobank reference values, taking gender, age and height into account (40).

Weight, BIA and HGS measures were performed in the outpatient clinic within office hours and prior to chemotherapy infusion to minimize the influence of chemotherapy and fluid infusion.

World Health Organization Performance Status (WHO PS) was assessed by the radiation oncologist at the initial visit. The Charlson Comorbidity Index (CCI) (41) was determined by review of individual medical records. The current malignant disease was not taken into account when rating “solid tumor” in the CCI. The cut-off for high CCI was set at ≥4.

Weight loss, FM loss, and FFM loss were turned into binary variables, where losses were compared to stable or increased mass. The cut-off for significant weight loss was set on −2% based on recent guidelines (42). To minimize potential effects of measurement errors, the cut-off values for the specific mass losses (FM and FFM) were set at 1% mass loss.

Gross tumor volume (GTV) was retrieved from records of radiation dosimetry data and divided in GTV of primary tumor (GTVp), GTV of involved lymph nodes (GTVn), and the total GTV of primary tumor and lymph nodes combined (GTVtotal). For LAHNSCC patients, all GTV data were retrieved from patients that underwent primary CRT/BRT. In patients undergoing post-operative CRT, GTV’s were only registered in...
case of tumor residue or regrowth in the period between surgery and start of radiotherapy.

Statistical Analysis

Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 25 (IBM Corp., Armonk, New York, USA). Descriptive statistics were reported in frequency distributions and absolute numbers by using independent samples t-test and \( \chi^2 \) test. Paired samples t-test was used to evaluate mass loss.

Survival analysis was performed through Kaplan Meier (Logrank Mantel–Cox test) and Cox regression. All variables were screened for their effect on OS through univariable cox regression. Factors with \( p < 0.30 \) were selected as potentially relevant predictor variables and were entered in a multivariable cox regression model. Stepwise backward elimination was carried out to omit all variables without an effect on OS from the model using a \( p \)-value for selection of 0.10.

RESULTS

Patients and Baseline Characteristics

Between January 2013 and July 2015, 172 patients with pathologically proven stage III NSCLC were referred to MAASTRO Clinic for concurrent CRT. In 124 patients, HGS and BIA measurements were performed at baseline and during treatment (part I). Sixty-four of the 124 NSCLC patients had histologically proven SCC and were included in part II of the study. Hundred-ninety-two LAHNSCC patients were treated with primary or adjuvant CRT/BRT between 2013 and 2016. Baseline and follow-up measurements in week 3 of CRT were available in 109 patients (part I), of which 61 were HPV–tumors receiving cisplatin as radiosensitizer (part II). Table 1 summarizes the baseline patient characteristics.

Part I—Prognostic Value of Baseline Characteristics for Overall Survival

A Cox regression analysis was performed in the total cancer population (\( n = 233 \)) to determine any confounding factors for OS within the baseline characteristics (Table 2). Using univariable analysis for the total population, the following variables yielded a \( p < 0.30 \) and were considered potentially relevant prognostic factors suitable for multivariate analysis: age, WHO PS, CCI, cancer site (NSCLC vs. LAHNSCC), history of COPD, FFMI<10, HGS<10, and GTV. Using multivariable Cox regression analysis, only CCI>4, cancer site being NSCLC, FFMI<10, HGS<10, and GTV_total remained statistically significant and were considered independent prognostic factors for OS. Kaplan Meier survival curve plotted in Figure 1 shows significant differences in OS for 4 different categories: LAHNSCC patients with normal FFMI, LAHNSCC patients with FFMI<10, NSCLC patients with normal FFMI, and NSCLC patients with FFMI<10 (Logrank Mantel Cox \( p < 0.001 \)). Two and 5 year OS rate for LAHNSCC patients with normal FFMI was 85 and 69%, respectively, compared to 68 and 45% for LAHNSCC patients with FFMI<10. For NSCLC patients, 2 and 5 year OS rate was 57 and 34%, respectively, for those with normal FFMI, compared to 35 and 24% for NSCLC patients with FFMI<10.

### Table 1 | Baseline characteristics (\( n = 233 \)).

| Variables       | Variables       |
|-----------------|-----------------|
| Gender          | Male            | 159 |
| Age             | Female          | 74  |
| Smoking status  | Mean ± SD, years| 62 ± 9 |
| Cancer site     | Active/former   | 214 |
|                 | Never           | 14  |
|                 | Unknown         | 5   |
| Histology       | Lungs           | 124 |
|                 | Head and neck   | 109 |
| GTV_total       | Squamous        | 173 |
|                 | Non-squamous    | 60  |
|                 | Total (Mean ± SD, cm³) | 52.1 ± 88.4 |
|                 | Squamous NSCLC  | 86.2 ± 131.9 |
|                 | Non-squamous NSCLC | 69.4 ± 86.5 |
|                 | Primary LAHNSCC | 29.3 ± 35.5 |
|                 | Post-op LAHNSCC | 4.6 ± 4.4 |
| GTV_total       | Total (Mean ± SD, cm³) | 19.0 ± 26.5 |
|                 | Squamous NSCLC  | 24.9 ± 30.6 |
|                 | Non-squamous NSCLC | 23.4 ± 23.3 |
|                 | Primary LAHNSCC | 16.5 ± 27.0 |
|                 | Post-op LAHNSCC | 8.9 ± 14.8 |
| Mean heart dose (NSCLC only) | Total (Mean ± SD, cm³) | 713.3 ± 91.8 |
| Systemic therapy | Platinum + etoposide (NSCLC) | 124 |
|                 | Platinum (LAHNSCC) | 82  |
|                 | Ceftazidim (LAHNSCC) | 27  |
| BMI (kg/m²)     | Total           | 24.4 ± 4.2 |
|                 | Male            | 24.8 ± 4.1 |
|                 | Female          | 23.5 ± 4.4 |
| FMI (kg/m²)     | Total           | 6.4 ± 2.6 |
|                 | Male            | 6.4 ± 2.6 |
|                 | Female          | 7.7 ± 3.2 |
| FFMI (kg/m²)    | Total           | 17.6 ± 2.5 |
|                 | Male            | 18.4 ± 2.2 |
|                 | Female          | 15.8 ± 1.9 |
| CCI             | 0–3             | 175 |
|                 | 4 or higher     | 58  |
| Disease stage NSCLC only | IA | 52  |
|                 | IB               | 53  |
|                 | IIC              | 19  |
| Disease stage LAHNSCC only | II | 2  |
|                 | III              | 19  |
| Dysphagia LAHNSCC only | CTCAE ≥ 2 | 30 |
|                 | CTCAE < 2       | 79  |
| P16 status LAHNSCC only | Positive oropharynx tumor | 23 |
|                 | Others           | 86  |
|                 | Primary          | 86  |
|                 | Adjuvant         | 23  |

Disease stage is based on TNM 7 classification ([43]). GTV<sub>total</sub> gross tumor volume of primary tumor; GTV<sub>primary</sub> gross tumor volume of lymph nodes involved; GTV<sub>combined</sub> GTV of both primary tumor and lymph nodes; BMI, body mass index; FMI, fat mass index; FFMI, fat free mass index; P16, tenth percentile according to reference values Spruit ([10]) and Schutz ([11]); HGS, hand grip strength; WHO PS, world health organization performance status; CCI, Charlson comorbidity index; COPD, chronic obstructive pulmonary disease. P16 is a surrogate marker for Human Papillomavirus infection, Mean values are presented ± SD. "Only from five patients with tumor residual or regrowth after surgery."
TABLE 2 | Cox regression analysis of baseline characteristics on OS (n = 233).

| Covariate                  | Univariate analysis | | | | Multivariate analysis | | | |
|----------------------------|---------------------|---|---|---|---------------------|---|---|
|                            | HR  | 95% CI     | p-value | HR  | 95% CI     | p-value |
| Male gender                | 1.10 | 0.75 1.62  | 0.62 | 1.78 | 0.94 3.38  | 0.08 |
| Age                        | 1.03 | 1.01 1.06  | 0.004 | 1.52 | 1.02 2.27  | 0.04 |
| WHO PS (≥ 2)               | 2.49 | 1.37 4.53  | 0.003 | 1.78 | 0.94 3.38  | 0.08 |
| CCI ≥ 4                    | 1.89 | 1.30 2.76  | 0.001 | 1.52 | 1.02 2.27  | 0.04 |
| Active/past smoker         | 1.13 | 0.60 2.12  | 0.70 | 2.12 | 1.40 3.22  | <0.001|
| Cancer site (NSCLC)        | 2.51 | 1.72 3.67  | <0.001| 2.12 | 1.40 3.22  | <0.001|
| History of COPD*           | 1.35 | 0.93 1.97  | 0.12 | 2.12 | 1.40 3.22  | <0.001|
| FFMI ≤ P10                 | 1.61 | 1.12 2.31  | 0.01 | 1.64 | 1.13 2.39  | 0.01 |
| FMI ≤ P10                  | 1.06 | 0.63 1.79  | 0.83 | 2.30 | 1.33 3.97  | 0.003 |
| HGS < P10                  | 2.51 | 1.48 4.26  | 0.001 | 2.30 | 1.33 3.97  | 0.003 |
| GTVp                       | 1.003 | 1.001 1.004 | 0.001 | 1.002 | 1.000 1.004 | 0.02 |
| GTVn                       | 1.009 | 1.004 1.014 | 0.001 | 1.002 | 1.000 1.004 | 0.02 |
| GTVtotal                   | 1.003 | 1.002 1.005 | <0.001| 1.002 | 1.000 1.004 | 0.02 |

Disease stage is based on TNM 7 classification (43). *Two missing. WHO PS, world health organization performance status; CCI, Charlson comorbidity index; COPD, chronic obstructive pulmonary disease; FMI, fat mass index; FFMI, fat free mass index; P10, tenth percentile according to reference values Spruit (40) and Schutz (39); HGS, handgrip strength; GTVp, gross tumor volume of primary tumor; GTVn, gross tumor volume of lymph nodes involved; GTVtotal, combined GTV of both primary tumor and lymph nodes. Underlined values indicate p value below 0.30. Bold values indicate statistical significance at the p value of 0.050.

FIGURE 1 | Kaplan Meier survival plot of baseline FFMI < P10 per cancer site.
Part II—Fat Mass, Fat Free Mass, and Handgrip Strength Changes

As stated in the method section, a subanalysis was performed to rule out potential confounders affecting weight loss. Supplementary Table 1 provides an overview of baseline characteristics of the 64 sNSCLC and 61 HPV− LAHNSCC patients. No statistically significant group differences were observed for the variables gender, smoking status, BMI, FMI, FFMI, HGS, WHO PS, and history of COPD. Mean GTV’s were significantly higher in sNSCLC patients and a CCI ≥ 4 was more prevalent in sNSCLC patients compared to HPV− LAHNSCC patients, which might be explained by an additional significantly younger age of the latter group.

To evaluate the effect of early mass loss (FM or FFM) on OS, Cox regression analysis was performed for the sNSCLC (n = 64) and HPV− LAHNSCC (n = 61) subgroup separately. Multivariable Cox regression analysis in the sNSCLC population showed the independent prognostic value of age [HR 1.08 [95%CI 1.03–1.14] p = 0.001], WHO PS ≥ 2 [HR 2.59 [95%CI 1.05–6.36] p = 0.04], FM loss >1% in first 3 weeks of therapy [HR 3.80 [95%CI 1.79–8.06] p = 0.001], and GTVα [HR 1.016 [95%CI 1.006–1.026] p = 0.002]. A trend of worse OS could be observed in case of FFM loss >1% [HR 1.85 [95%CI 0.90–3.82] p = 0.09] (Table 3A and Figure 2). In HPV− LAHNSCC patients treated with CRT, multivariable analysis displayed no independent prognostic factors (Table 3B).

The proportion of patients experiencing significant weight loss (>2%) during first 3 weeks of therapy did not significantly differ between sNSCLC and HPV− LAHNSCC, 24/64 vs. 23/61, respectively (p = 0.98). In these weight losing patients, proportional weight loss did not significantly differ between sNSCLC and LAHNSCC, −4.8 ± 2.6% (mean ± SD) and −5.2 ± 2.1%, respectively p = 0.62. However, when distinguishing the composition of body mass loss, a significant difference was observed: FM change was −1.4 ± 14.5% and −8.7 ± 9.0% in sNSCLC and HPV− LAHNSCC patients, respectively (p < 0.05). FFM change was −5.6 ± 6.3 and −4.0 ± 4.3% for sNSCLC and HPV− LAHNSCC, respectively (p = 0.31). Specification of the composition of body mass loss for the total 125 patients is provided in the Supplementary Table 2.

DISCUSSION

This study was conducted to elucidate the effect of body composition and HGS before start of treatment and early changes of FM, FFM, and HGS during CRT on OS in patients diagnosed with NSCLC or LAHNSCC.

HGS and FFMI <P10 at baseline as a surrogate marker for muscle wasting were both negative prognostic factors for OS, independent of cancer site (NSCLC or LAHNSCC) and GTV. This is in full accordance with the current literature on muscle wasting in cancer patients (44–46). While the effect of muscle wasting on OS is not new, our results emphasize that simple measurements such as BIA and HGS can detect muscle wasting in NSCLC and LAHNSCC patients in an early phase of treatment.

Previously, our group revealed the prognostic significance of early weight loss in NSCLC patients (20). In the current study, we confirmed this finding and unraveled the components of this early weight loss and the effect on OS. Strikingly, in multivariable Cox regression analysis, FM loss remained a significant prognostic factor for OS in sNSCLC, but not in HPV− LAHNSCC patients.

The analysis of specific mass loss patterns was carried out presuming comparable patient characteristics between both cancer populations, by leaving out adenocarcinoma, HPV+ LAHNSCC, and cetuximab as systemic therapy (part II). However, our analysis revealed a higher CCI in sNSCLC, as a result of an additional higher mean age of this group, which is a parameter in the CCI calculation. Also, GTV was higher in NSCLC compared to LAHNSCC. Yet, despite these differences, body composition parameters were similar for both groups, which allowed further comparison.

While we hypothesized to find a higher weight loss in LAHNSCC due to tumor location related factors impairing oral intake, our results show otherwise. The percentage of early weight loss (first 3 weeks of CRT) was comparable between NSCLC and LAHNSCC patients, and the proportion of patients that experienced significant weight loss (>2%) was similar between both cancer sites.

Nevertheless, evaluating the composition of weight loss, in particular FM and FFM loss, our data revealed different patterns for both sub groups. CRT receiving HPV− LAHNSCC patients with significant weight loss seemed to lose FM in particular, which was significantly higher than in sNSCLC patients. sNSCLC patients with significant weight loss (>2%) seem to lose predominantly FFM. Both sNSCLC and HPV− LAHNSCC patients experiencing significant weight loss showed a decrease in FFM, with a trend toward higher FFM loss in sNSCLC patients.

We believe potential explanations for the differences in body composition changes and the prognostic value of early weight loss are multifactorial, including patient characteristics, tumor metabolism and load, and treatment related factors.

The higher CCI and the higher prevalence of COPD in sNSCLC patients suggest an additional burden on systemic inflammation, which is known to contribute to muscle wasting (47). However, one would also expect baseline group differences in body composition, which were not observed. Additionally, there could be an underestimation of the COPD prevalence in LAHNSCC patients as these patients are not routinely tested for COPD. Furthermore, when evaluating the subgroup of HPV− LAHNSCC patients receiving cisplatin as radiosensitizer (part II), the CCI may be lower than in sNSCLC due to the strictly applied selection criteria for receiving platinum-based CRT in LAHNSCC. In case of significant (cardiac, pulmonary, and renal) comorbidity, platinum based treatment is withheld in LAHNSCC and cetuximab is used as radiosensitizer. The latter was excluded in the subanalysis of part II. Therefore, organ dysfunction related to comorbidities is probably barely present in the HPV− LAHNSCC treated with cisplatinum-based CRT subgroup, in contrast to the sNSCLC patients,
### Table 3A | Cox regression analysis of early mass loss in sNSCLC (n = 64).

| Covariate                        | Univariate analysis | Multivariate analysis |
|----------------------------------|---------------------|-----------------------|
|                                  | HR                  | 95% CI                | HR                    | 95% CI                |
|                                  | Lower               | Upper                 | p-value               | Lower               | Upper                 | p-value               |
| Male gender                      | 0.99                | 0.47 2.05             | 0.97                  | 1.08                 | 1.03 1.14             | 0.001                 |
| Age                              | 1.06                | 1.01 1.11             | 0.01                  | 2.59                 | 1.05 6.36             | 0.04                  |
| WHO PS (\(\geq 2\))             | 3.03                | 1.33 6.88             | 0.008                 |                      |                      |                      |
| CCI \(\geq 4\)                   | 1.35                | 0.74 2.48             | 0.33                  |                      |                      |                      |
| Active/past smoker               | 1.25                | 0.37 4.18             | 0.72                  |                      |                      |                      |
| History of COPD                  | 1.25                | 0.68 2.30             | 0.47                  |                      |                      |                      |
| Disease stage                    |                     |                       |                       |                      |                      |                      |
| IIA                               |                     | 0.53                  |                       |                      |                      |                      |
| IIB                               | 1.34                | 0.67 2.66             | 0.41                  |                      |                      |                      |
| IIIC                              | 1.53                | 0.70 3.34             | 0.29                  |                      |                      |                      |
| FFM loss >1%                     | 1.73                | 0.94 3.15             | 0.08                  | 1.85                 | 0.90 3.82             | 0.09                  |
| FM loss >1%                      | 2.23                | 1.23 4.06             | 0.008                 | 3.80                 | 1.79 8.06             | 0.001                 |
| HGS loss >1%                     | 0.87                | 0.48 1.57             | 0.64                  |                      |                      |                      |
| GTVp                             | 1.001               | 0.998 1.004           | 0.46                  |                      |                      |                      |
| GTVn                             | 1.008               | 1.001 1.016           | 0.03                  | 1.016                | 1.006 1.026           | 0.002                 |
| GTVn                              | 1.002               | 0.999 1.004           | 0.18                  |                      |                      |                      |
| Mean heart dose                  | 1.029               | 0.995 1.066           | 0.10                  |                      |                      |                      |

Disease stage is based on TNM 7 classification; Underlined values indicate p value below 0.30. Bold values indicate statistical significance at the p value of 0.050. WHO PS, world health organization performance status; CCI, Charlson comorbidity index; COPD, chronic obstructive pulmonary disease; FFM, fat free mass; FM, fat mass; HGS, handgrip strength; GTV\(_p\), gross tumor volume of primary tumor; GTV\(_n\), gross tumor volume of lymph nodes involved; GTV\(_{total}\), combined GTV of both primary tumor and lymph nodes.

### Table 3B | Cox regression analysis of early mass loss in HPV– LAHNSCC receiving platinum based systemic therapy (n = 61).

| Covariate                        | Univariate analysis | Multivariate analysis |
|----------------------------------|---------------------|-----------------------|
|                                  | HR                  | 95% CI                | HR                    | 95% CI                |
|                                  | Lower               | Upper                 | p-value               | Lower               | Upper                 | p-value               |
| Male gender                      | 2.93                | 0.87 9.45             | 0.08                  | 2.93                 | 0.87 9.45             | 0.08                  |
| Age                              | 0.98                | 0.93 1.02             | 0.34                  |                      |                      |                      |
| WHO PS (\(\geq 2\))             | 1.53                | 0.21 11.5             | 0.68                  |                      |                      |                      |
| CCI \(\geq 4\)                   | 1.34                | 0.18 10.0             | 0.77                  |                      |                      |                      |
| Active/past smoker               | 0.48                | 0.14 1.62             | 0.24                  |                      |                      |                      |
| History of COPD                  | 1.09                | 0.42 2.78             | 0.86                  |                      |                      |                      |
| Disease stage                    |                     |                       |                       |                      |                      |                      |
| I                               | 0.80                |                       |                       |                      |                      |                      |
| II                               | 0.39                | 0.04 3.50             | 0.40                  |                      |                      |                      |
| IVA                              | 0.57                | 0.08 4.34             | 0.59                  |                      |                      |                      |
| IVb                              | 0.37                | 0.02 5.97             | 0.48                  |                      |                      |                      |
| Dysphagia CTCAE \(\geq 2\)      | 0.87                | 0.32 2.35             | 0.78                  |                      |                      |                      |
| Adjuvant                         | 0.99                | 0.40 2.4              | 0.48                  |                      |                      |                      |
| FFM loss >1%                     | 1.03                | 0.45 2.39             | 0.94                  |                      |                      |                      |
| FM loss >1%                      | 1.63                | 0.60 4.41             | 0.34                  |                      |                      |                      |
| HGS loss >1%                     | 1.25                | 0.51 3.06             | 0.63                  |                      |                      |                      |
| GTV\(_p\)                        | 1.004               | 0.996 1.012           | 0.33                  |                      |                      |                      |
| GTV\(_n\)                        | 1.005               | 0.980 1.031           | 0.68                  |                      |                      |                      |
| GTV\(_{total}\)                  | 1.004               | 0.996 1.012           | 0.28                  |                      |                      |                      |

Disease stage is based on TNM 7 classification; Underlined values indicate p value below 0.30. WHO PS, world health organization performance status; CCI, Charlson comorbidity index; COPD, chronic obstructive pulmonary disease; CTCAE, common terminology criteria of adverse events; FFM, fat free mass; FM, fat mass; HGS, handgrip strength; GTV\(_p\), gross tumor volume of primary tumor; GTV\(_n\), gross tumor volume of lymph nodes involved; GTV\(_{total}\), combined GTV of both primary tumor and lymph nodes.
Tumor characteristics such as location, size, and tumor metabolism differ between the sNSCLC and HPV– LAHNSCC group. The higher amount of FM loss in LAHNSCC might be due to oral intake-related factors (tumor location, prior head and neck surgery, odynophagia, or dysphagia) rather than high catabolic activity causing muscle wasting, which was more pronounced in NSCLC. Early dietary consultation in LAHNSCC has a positive effect on weight maintenance (49). Conceivably, administration of oral nutritional supplements or tube feeding in LAHNSCC may have blurred the effects of weight loss on OS. Unfortunately, reliable information on the exact nutritional support given could not be retrieved from the medical records. Interventions to improve or maintain body weight and muscle mass in particular are under investigation, but have not resulted in standardized supportive treatment protocols yet. The current study results support the need for further research into interventions for these patient groups.

Yet, a key point in cancer cachexia is that it cannot be fully reversed by nutritional support, and systemic inflammation plays an important role in both muscle and FM loss (50). Both tumor and host tissue can produce cytokines leading to inflammation. It has been reported that systemic inflammation is correlated with tumor volume (51) and previous studies have shown the prognostic value of GTV (52). Our results show the prognostic value of GTV independent of baseline FFMI< P10, suggesting higher systemic inflammation in more voluminous tumors (51).

It is likely that also oncological treatment related factors play a role in the prognostic value of early mass loss in
NSCLC but not in LAHNSCC. While concurrent systemic therapy for LAHNSCC consists of cisplatin only, platinum derivatives combined with etoposide are used for NSCLC. Platinum-based regimens are known to induce the release of pro-cachectic cytokines and myostatin, activating the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) signaling pathway, which is associated with muscle wasting (53). Etoposide has also shown to induce muscle wasting (54). The combination of both drugs might accelerate muscle wasting in NSCLC. Also, GTV was higher in NSCLC vs. LAHNSCC, meaning that more cells will experience DNA-damage during radiation, which can result in a higher pro-inflammatory environment (55). We are aware that our research has limitations. Generally accepted cut off points for FM and FFMI loss have not been defined in the literature. For exploratory purposes, we chose an arbitrary cut-off on an empirical basis. Additionally, standardized information on oral intake and the use of nutritional supplements or tube feeding was lacking. Evaluating FM through BIA does not provide information on the type of fat being lost, e.g., visceral adipose tissue or subcutaneous adipose tissue. Also, BIA results should be interpreted with caution in case of changes in the patients’ hydration status and physical exercise. The authors are aware that due to these limitations, BIA is not considered the gold standard. Furthermore, BIA is not suitable for independently identifying changes in skeletal muscle index. However, the FFMI can be measured using BIA and is a realistic reflection of skeletal muscle mass. The final limitation we would like to address is that our study did not include progression or disease free survival analyses. However, CCI was added in our OS analyses to adjust for the effects of comorbidities on OS.

In conclusion, our study showed that low (<P<0.1) HGS and FFMI at baseline are independent prognostic factors for poor OS in NSCLC and LAHNSCC patients treated with CRT/BRT with curative intent. Despite comparable patient characteristics, treatment, and histological tumor characteristics, the specific composition of mass loss during the first 3 weeks of CRT significantly differs between sNSCLC and HPV– LAHNSCC patients and early loss of FM was prognostic in sNSCLC only. Further research is needed to unravel the pathophysiology of early weight loss during oncological treatment in order to develop patient-tailored intervention studies.

**REFERENCES**

1. Dixit R, Weissfeld JL, Wilson DO, Balogh P, Suflka P, Siegfried JM, et al. Incidence of head and neck squamous cell carcinoma among subjects at high risk of lung cancer: results from the pittsburgh lung screening study. *Cancer*. (2015) 121:1431–5. doi: 10.1002/cncr.29189
2. Ichinose J, Shinozaki-Ushiku A, Nagayama K, Nitadori JI, Anraku M, Fukayama M, et al. Immunohistochemical pattern analysis of squamous cell carcinoma: lung primary and metastatic tumors of head and neck. *Lung Cancer*. (2016) 100:96–101. doi: 10.1016/j.lungcan.2016.08.003
3. Mouronte-Roibas C, Leiro-Fernandez V, Ruano-Ravina A, Ramos-Hernandez C, Abal-Arca J, Parente-Lamelas I, et al. Chronic obstructive pulmonary disease in lung cancer patients: prevalence, underdiagnosis, clinical characterization. *Respiration*. (2018) 95:414–21. doi: 10.1159/000487243
4. Powell HA, Iyen-Omofoman B, Baldwin DR, Hubbard RB, Tata LJ. Chronic obstructive pulmonary disease and risk of lung cancer: the importance of smoking and timing of diagnosis. *J Thorac Oncol*. (2013) 8:6–11. doi: 10.1097/JTO.0b013e318274a7dc
5. Eytan DF, Blackford AL, Eisele DW, Fakhry C. Prevalence of comorbidities among older head and neck cancer survivors in the united states. *Otolaryngol Head Neck Surg*. (2019) 160:85–92. doi: 10.1177/0194599818796163
6. Gottlieb M, Marsaa K, Godtfredsen NS, Mellemgaard A. Prevalence and management of pulmonary comorbidity in patients with

**DATA AVAILABILITY STATEMENT**

The data analyzed in this study is subject to the following licenses/restrictions: The datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request. Requests to access these datasets should be directed to AW, rianne.willemsen@maastrichtuniversity.nl.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Institutional Review Board of MAASTRO Clinic. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

**AUTHOR CONTRIBUTIONS**

AW and JD conducted research, collected data, analyzed data, and wrote the manuscript. AS and A-MD were involved in research design, data analysis, and writing. AH and LB were involved for their expert opinion in data interpretation and translation to clinical practice. FH and DD provided essential material and were involved for their expert opinion in data interpretation and translation to clinical practice. All authors contributed to the article and approved the submitted version.

**FUNDING**

This research was supported by the NUTRIM Graduate Programme.

**ACKNOWLEDGMENTS**

The authors would like to thank Yves Willems for the retrieval of GTV data, and Karin Sanders for the provision of supportive data.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2020.600612/full#supplementary-material
lungs and head and neck cancer. *Acta Oncol.* (2015) 54:767–71. doi: 10.3109/0284186X.2014.1001496

7. Auperin A, Le Pechoux C, Rolland E, Curran W, Furuse K, Fourpil N, et al. Meta-analysis of concomitant versus sequential radiotherapy in locally advanced non-small-cell lung cancer. *J Clin Oncol.* (2010) 28:2181–90. doi: 10.1200/JCO.2009.26.2543

8. Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC update from PACIFIC. *J Thorac Oncol.* (2020) 15:288–93. doi: 10.1016/j.jtho.2019.01.002

9. Pignon JP, Le Maitre A, Maillard E, Bourhis J, MNC Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. *Radiother Oncol.* (2009) 92:4–14. doi: 10.1016/j.radonc.2009.04.014

10. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. *Lancet Oncol.* (2010) 11:21–8. doi: 10.1016/S1470-2045(09)70311-0

11. Pharmeneqti QC, Spoelstra FOB, Verbakel W, Postmus PE, Melissan CF, Maassen van den Brink KJ, et al. Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity. *Ann Oncol.* (2011) 22:132–8. doi: 10.1093/annonc/mdq316

12. Fourrel P, Robinet G, Thomas P, Souquet PJ, Lena H, Vergnenegre A, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: groupe lyon- saint-etienne d'oncologie thoracique-groupe francais de pneumo-cancerologie NPC 95-01 study. *J Clin Oncol.* (2005) 23:5910–7. doi: 10.1200/JCO.2005.03.070

13. Albain KS, Swann RS, Rasch VW, Turrisi AT III, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. *Lancet.* (2009) 374:379–86. doi: 10.1016/S0140-6736(09)60737-6

14. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. *N Engl J Med.* (2006) 354:567–78. doi: 10.1056/NEJMoa053422

15. Blanchard EM, Moon J, Hesketh PJ, Kelly K, Wozniak AJ, Crowley J, et al. Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of southwest oncology group trials 9308 and 9509. *J Thorac Oncol.* (2011) 6:115–20. doi: 10.1097/JTO.0b013e3181bfebd

16. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol.* (2011) 12:489–95. doi: 10.1016/S1470-2045(10)70218-7

17. Martin L, Birdsell L, Macdonald N, Reiman T, Curran WJ, Furuse K, et al. Characteristics and survival of head and neck cancer by HPV status: a cancer registry-based study. *Int J Cancer.* (2012) 131:1799–806. doi: 10.1002/ijc.25000

18. Parahoo RS, Semple CJ, Killough S, McCaughan E. The experience among patients with multiple dental loss as a consequence of treatment oncological treatment: A 5-year prospective study. *Support Care Cancer.* (2017) 25:901–7. doi: 10.1007/s00520-016-3513-7

19. Pan W, Li X, Jin Y. Body composition changes in patients with head and neck cancer under concurrent chemoradiotherapy: a longitudinal assessment of muscle from regular chest computed tomography scans: L1 and pectoralis muscle compared to L3 as reference in non-small cell lung cancer patients. *Radiother Oncol.* (2018) 129:33–40. doi: 10.1016/j.radonc.2018.04.006

20. Burtin C, Beuzidchout J, Sanders KJC, Dingemans AC, Schols A, Peeters STH, et al. Handgrip weakness, low fat-free mass, and overall survival in non-small cell lung cancer treated with curative-intent radiotherapy. *J Cachexia Sarcopenia Muscle.* (2020) 11:424–31. doi: 10.1007/jcn.12526

21. Ferrari B, Neves PM, Santos T, Capelas ML, Makite I, Ravasco P. Body composition changes in patients with head and neck cancer under active treatment: a scoring review. *Support Care Cancer.* (2020) 28:4613–25. doi: 10.1007/s00520-020-04587-y

22. Ding H, Dou S, Ling Y, Zhu G, Wang Q, Wu Y, et al. Longitudinal body composition changes and the importance of fat-free mass index in locally advanced nasopharyngeal carcinoma patients undergoing concurrent chemoradiotherapy. *Integ Cancer Ther.* (2018) 17:1125–31. doi: 10.1177/153475418807969

23. Jeffrey TW, Schuurbiers OC, Kaanders JH, Looijen-Salamon MG, de Geus-Oef LF, Verhagen AF, et al. Differences in metabolism between adenocarcinoma and squamous-cell non-small-cell lung cancers: spatial distribution and prognostic value of GLUT1 and MCT4. *Lung Cancer.* (2012) 76:316–23. doi: 10.1016/j.lungcan.2011.11.006

24. Schuurbiers OC, Meijer TW, Kaanders JH, Looijen-Salamon MG, de Geus-Oef LF, van der Drift MA, et al. Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18FDG-PET for adenocarcinoma and squamous cell carcinoma. *J Thorac Oncol.* (2014) 9:1483–93. doi: 10.1097/JTO.0000000000000286

25. Jung YS, Najy AJ, Huang W, Sethi S, Snyder M, Sakr W, et al. HPV-associated differential regulation of tumor metabolism in oropharyngeal head and neck cancer. *Oncotarget.* (2017) 8:51350–41. doi: 10.18632/oncotarget.17887

26. Sethi S, Ali-Fehmi R, Franceschi S, Struijk L, van Doorn LJ, Quint W, et al. Characteristics and survival of head and neck cancer by HPV status: a cancer registry-based study. *Int J Cancer.* (2012) 131:1799–806. doi: 10.1002/ijc.26500

27. Parahoo RS, Semple CJ, Killough S, McCaughan E. The experience among patients with multiple dental loss as a consequence of treatment for head and neck cancer: a qualitative study. *J Dent.* (2019) 82:30–37. doi: 10.1016/j.jdent.2019.01.010

28. de Groot RJ, Wetzels JW, Merxk MAW, Rosenberg A, de Haan AFI, van der Bilt A, et al. Masticatory function and related factors after oral oncological treatment: A 3-year prospective study. *Head Neck.* (2019) 41:216–24. doi: 10.1002/hed.25445

29. De Buysscher D, Fairwe-Finn C, Moeller D, Nestle U, Hurkmans CW, Le Pechoux C, et al. European organization for research and treatment of cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. *Radiother Oncol.* (2017) 124:1–10. doi: 10.1016/j.radonc.2017.06.003

30. Vansteenkiste J, De Ruyscher D, Eberhardt WE, Lim E, Senan S, Felip E, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* (2013) 24(Suppl. 6):vii89–98. doi: 10.1093/annonc/mdt424

31. Blanchard P, Bajuat B, Holostenc V, Bourreldem A, Baye C, Bourhis J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. *Radiother Oncol.* (2011) 100:33–40. doi: 10.1016/j.radonc.2011.05.036
39. Schutz Y, Kyle UU, Pichard C. Fat-free mass index and fat mass index percentiles in Caucasians aged 18-98 y. *Int J Obes Relat Metab Disord.* (2002) 26:953–60. doi: 10.1038/sj.ijo.0802037

40. Spruit MA, Sillen MJ, Groenen MT, Wouters EF, Franssen FM. New normative values for handgrip strength: results from the UK biobank. *J Am Med Dir Assoc.* (2013) 14:775.e5–11. doi: 10.1016/j.jamda.2013.06.013

41. Charlton ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* (1987) 40:373–83. doi: 10.1016/0021-9681(87)90171-8

42. Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, et al. Management of cancer cachexia: ASCO guideline. *J Clin Oncol.* (2020) 38:2438–53. doi: 10.1200/JCO.20.00611

43. Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol.* (2010) 17:1471–4. doi: 10.1245/s10434-010-0985-4

44. Aleixo GFP, Williams GR, Nyrop KA, Muss HB, Shachar SS. Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review. *Breast Cancer Res Treat.* (2019) 177:569–79. doi: 10.1007/s10549-019-05352-3

45. Yang M, Shen Y, Tan L, Li W. Prognostic value of sarcopenia in lung cancer: a systematic review and meta-analysis. *Chest.* (2019) 156:101–11. doi: 10.1016/j.chest.2019.04.115

46. Su H, Ruan J, Chen T, Lin E, Shi L. CT-assessed sarcopenia is a predictive factor for both long-term and short-term outcomes in gastrointestinal oncology patients: a systematic review and meta-analysis. *Cancer Imaging.* (2019) 19:82. doi: 10.1186/s40644-019-0270-0

47. Gan WQ, Man SE, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. *Thorax.* (2004) 59:574–80. doi: 10.1136/thx.2003.019588

48. Griesinger F, Korol EE, Kayaniyl S, Varol N, Ebner T, Goring SM. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: a meta-analysis. *Lung Cancer.* (2019) 135:196–204. doi: 10.1016/j.lungcan.2019.07.010

49. Langius JA, Zandbergen MC, Eerenstein SE, van Tulder MW, Leemans CR, Kramer MH, et al. Effect of nutritional interventions on nutritional status, quality of life and mortality in patients with head and neck cancer receiving (chemo)radiotherapy: a systematic review. *Clin Nutr.* (2013) 32:671–8. doi: 10.1016/j.clnu.2013.06.012

50. Ebadi M, Mazurak VC. Evidence and mechanisms of fat depletion in cancer. *Nutrients.* (2014) 6:5280–97. doi: 10.3390/nu6115280

51. Salem A, Mistry H, Backen A, Hodgson C, Koh P, Dean E, et al. Cell death, inflammation, tumor burden, and proliferation blood biomarkers predict lung cancer radiotherapy response and correlate with tumor volume and proliferation imaging. *Clin Lung Cancer.* (2018) 19:239–48.e7. doi: 10.1016/j.cllc.2017.12.002

52. Dehing-Oberije C, Yu S, De Ruyscher D, Meersschout S, Van Beek K, Lievens Y, et al. Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. *Int J Radiat Oncol Biol Phys.* (2009) 74:355–62. doi: 10.1016/j.ijrobp.2008.08.052

53. Sakai H, Sagara A, Arakawa K, Sugiyama R, Hirotsuki A, Takase K, et al. Mechanisms of cisplatin-induced muscle atrophy. *Toxicol Appl Pharmacol.* (2014) 278:190–9. doi: 10.1016/j.taap.2014.05.001

54. Damrauer JS, Stadler ME, Acharya S, Baldwin AS, Couch ME, Guttridge DC. Chemotherapy-induced muscle wasting: association with NF-κB and cancer cachexia. *Eur J Transl Myol.* (2018) 28:7590. doi: 10.4081/ejtm.2018.7590

55. McKeelvey KJ, Hudson AL, Back M, Eade T, Diakos CI. Radiation, inflammation and the immune response in cancer. *Mamm Genome.* (2018) 29:843–65. doi: 10.1007/s00335-018-9777-0

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.